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OBJECTIVES This biochemical study compared the extracellular matrix of normal mitral valves and
myxomatous mitral valves with either unileaflet prolapse (ULP) or bileaflet prolapse (BLP).
BACKGROUND Myxomatous mitral valves are weaker and more extensible than normal valves, and
myxomatous chordae are more mechanically compromised than leaflets. Despite histological
evidence that glycosaminoglycans (GAGs) accumulate in myxomatous valves, previous
biochemical analyses have not adequately examined the different GAG classes.
METHODS Leaflets and chordae from myxomatous valves (n  41 ULP, 31 BLP) and normal valves (n
 27) were dried, dissolved, and assayed for deoxyribonucleic acid, collagen, and total GAGs.
Specific GAG classes were analyzed with selective enzyme digestions and fluorophore-
assisted carbohydrate electrophoresis.
RESULTS Biochemical changes were more pronounced in chordae than in leaflets. Myxomatous leaflets
and chordae had 3% to 9% more water content and 30% to 150% higher GAG concentrations
than normal. Collagen concentration was slightly elevated in the myxomatous valves.
Chordae from ULP had 62% more GAGs than those from BLP, primarily from elevated
levels of hyaluronan and chondroitin-6-sulfate.
CONCLUSIONS The GAG classes elevated in the myxomatous chordae are associated with matrix micro-
structure and elastic fiber deficiencies and may influence the hydration-related “floppy” nature
of these tissues. These abnormalities may be related to the reported mechanical weakness of
myxomatous chordae. The biochemical differences between ULP and BLP confirm previous
mechanical and echocardiographic distinctions. (J Am Coll Cardiol 2003;42:271–7)
© 2003 by the American College of Cardiology Foundation
Myxomatous changes in mitral valves affect 2.4% to 5% of
men and women in the U.S. and other industrialized
nations (1,2), but the pathogenesis of this disease remains
unknown. The characteristic gross changes in myxomatous
mitral valves (thickening, enlargement, leaflet hooding,
annular dilation, elongated and/or ruptured chordae) (3) are
accompanied at the microscopic level by fragmented, irreg-
ular elastin and collagen (4), abundant matrix metallopro-
teases (5), and an accumulation of glycosaminoglycans
(GAGs) and proteoglycans (4,6,7), particularly in the spon-
giosa layer of the leaflets (4).
Despite visible changes in the leaflet spongiosa, previous
biochemical analyses of myxomatous valves have focused
less on GAGs and more on collagen. Two studies suggested
that myxomatous leaflets have amplified collagen synthesis
(8,9). Another study reported that myxomatous chordae but
not leaflets have elevated collagen concentrations relative to
normals (10). This same study found total GAG concen-
trations almost double those of controls.
Because proteoglycans and GAGs serve several purposes
in connective tissues (11), including hydration, compliance,
viscosity, and regulation of collagen fibrillogenesis, their
accumulation in myxomatous tissues likely influences the
accompanying extracellular matrix and the mechanical be-
havior of the mitral valve. Mitral valves normally contain
several classes of GAGs (12), usually within proteoglycans,
such as versican or decorin. Three studies have suggested
that the greater GAG concentration of myxomatous valves
results mainly from an elevation in the GAG hyaluronan
(HA) (10,13,14), but only one of these studies actually
investigated specific GAGs in human myxomatous valve
tissues (via enzymatic histology) (14).
It is also unclear whether myxomatous changes affect the
different components of the mitral valve apparatus to the
same extent. We have previously shown that the mechanical
abnormalities of myxomatous valves are far more severe in
the chordae than in the leaflets (15,16). Indeed, the greater
extensibility and lower strength of myxomatous chordae is
consistent with reports that most cases of myxomatous
mitral regurgitation that require surgical correction are due
to chordal elongation or rupture, as opposed to isolated
leaflet prolapse due to annular dilation (3). We therefore
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hypothesized that myxomatous disease imparts different
biochemical effects on the extracellular matrix of the mitral
leaflets and chordae, which then result in their varying
functional severities. Furthermore, we suspected that there
may be additional biochemical differences between the two
most common presentations of myxomatous mitral valves—
unileaflet prolapse (ULP) and bileaflet prolapse (BLP). We
have reported previously that myxomatous valves with ULP
are weaker than valves with BLP (17). To test these
hypotheses, we compared concentrations of water, deoxyri-
bonucleic acid (DNA), collagen, total GAGs, and specific
GAG classes in normal and myxomatous mitral leaflets and
chordae and performed a subgroup comparison of ULP
versus BLP.
METHODS
Myxomatous mitral valve specimens were obtained from 72
patients after surgery to correct severe mitral regurgitation
due to a prolapsing valve (Table 1). The use of these tissues
was authorized by the Institutional Review Board. Two
patients underwent mitral valve replacement with a biopros-
thetic valve; the remainder underwent quadrilateral resec-
tion of the posterior leaflet and implantation of an annulo-
plasty ring. Eleven patients had 12 concomitant procedures
(7 coronary artery bypass grafts, 4 tricuspid valve repairs,
and 1 aortic valve replacement). Myxomatous classification
of the tissues was based on gross pathology, and the
presence of ULP or BLP was confirmed by surgical and
echocardiographic findings. Normal mitral valves were ob-
tained at autopsy (24 h post mortem) from people who
died of non-cardiac-related causes. All tissues were stored at
20°C before analysis. Our laboratory has determined that
valve tissues kept at 4°C retain their matrix-based mechan-
ical properties for up to five days. We therefore believe that
the extracellular matrix in these cadaveric valves was not
measurably degraded during the postmortem period.
Only posterior leaflets and associated chordae were stud-
ied, because these tissues are most commonly resected
during surgical repair of myxomatous valves, even in BLP
(3). The chordae from each specimen were cut free and
pooled for analysis. After the wet weights, lyophilized dry
weights, and water concentrations were determined, each
leaflet and pooled chordal sample was dissolved in 100 mM
ammonium acetate buffer (pH 7) containing proteinase-K
(1 mg/ml) at 60°C for 16 h (18). Aliquots were then taken
to measure the concentrations of hydroxyproline (for colla-
gen) (19), DNA (for cells) (20), and hexuronic acid (for
GAGs) (21). The total amount of GAGs was estimated by
both the hexuronic acid assay and by adding together the
amounts of the different GAG classes found by
fluorophore-assisted carbohydrate electrophoresis (FACE).
To quantify the different GAG classes, the samples were
analyzed by an enzymatic digestion followed by FACE (18).
For each sample, two identical aliquots containing at most 5
g of hexuronic acid were incubated with either: 1) 2 l of
hyaluronidase SD (Streptococcus dysgalactiae) plus 3 l of
chondroitinase ABC (Seikagaku America, Falmouth, Mas-
sachusetts; each 10 mU/l, termed HABC); or 2) 3 l of
chondroitinase ACII (10 mU/l, termed ACII) for 3 h at
37°C. The HABC treatment cleaves the HA, chondroitin
sulfate (CS), and dermatan sulfate (DS) chains into disac-
charides, but the ACII treatment will not cleave bonds
adjacent to iduronic acid (a component of DS). Therefore,
ACII provides a measure of the minimum CS concentra-
tion, allowing the maximum DS concentrations to be
estimated by subtraction from HABC. After digestion, the
samples were dried, fluorotagged, mixed with glycerol and
an internal standard (see below), and electrophoresed on a
monosaccharide gel as previously described (18). The gel
bands were imaged and analyzed using Gel-Pro (Media
Cybernetics, Silver Spring, Maryland).
Serial dilutions of 2-sulfated disaccharide (not found in
valves) were added to individual samples to provide an
internal calibration curve for fluorescence intensity (Fig. 1).
Enzyme digestion products were identified by correspon-
dence to bands in a disaccharide standard lane. The quantity
of each GAG was determined from the integrated optical
Abbreviations and Acronyms
ACII  chondroitinase ACII
BLP  bileaflet prolapse
CS  chondroitin sulfate
DNA  deoxyribonucleic acid
DS  dermatan sulfate
FACE  fluorophore-assisted carbohydrate
electrophoresis
GAG  glycosaminoglycan
HA  hyaluronan
HABC  hyaluronidase SD (Streptococcus dysgalactiae)
plus chondroitinase ABC
ULP  unileaflet prolapse
Table 1. Subject Group Characteristics
Normal ULP BLP
Sample size 33 41 30
Age, yrs* 47.2  12.3 57.2  11.9 55.1  12.3
Gender, male/female 25/8 30/11 19/11
Body surface area, m2 1.9  0.2 2.0  0.4 1.9  0.2
Atrial fibrillation, n (%) 4 (10) 5 (17)
Hypertension, n (%) 8 (20) 4 (13)
CHF, n (%) 2 (5) 2 (7)
MR severity† 3.9  0.3 3.6  0.4
LA diameter, mm 47.2  9.8 50.0  9.7
LVEDD, mm 58.2  7.8 56.3  8.9
LVESD, mm 35.1  8.5 32.8  7.7
Ejection fraction, % 59.8  8.8 58.6  3.4
Annular diameter, mm 43.4  5.8 42.9  5.3
PL length, mm 23.5  6.3 23.2  7.6
PL thickness, mm† 5.4  1.7 4.5  2.4
Data are given as mean  standard deviation. *p  0.01 normal vs. ULP; †p  0.05
ULP vs. BLP.
BLP  bileaflet prolapse; CHF  congestive heart failure; LA  left atrial;
LVEDD  left ventricular end-diastolic diameter; LVESD  left ventricular
end-systolic diameter; MR  mitral regurgitation; PL  posterior mitral leaflet;
ULP  unileaflet prolapse.
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density of the band, the calibration curve, and the aliquot
volume used for the enzyme digest. The total GAG con-
centration was obtained by summation of the HA and
CS/DS.
The resulting GAG profiles were used to calculate the
lengths of the CS/DS chains, which are highly specific to
particular types of proteoglycans (22,23). The average chain
length was calculated from the HABC digest lanes by
summing the total amount of the CS and DS disaccharides
(except the 2-sulfate) and dividing by the total amount of
saccharides at the non-reducing termini of the GAG chains.
The measured values from each sample were divided by
the sample dry and wet weights to obtain normalized
concentrations (wet-weight data not shown). To control for
differences in baseline characteristics (Table 1), which could
affect the size of the valve and its total matrix content, data
were examined as concentrations and were independent of
actual tissue dimensions. To avoid the confounding issue of
water content, the proportions of the different GAG classes
were also calculated relative to the total GAG quantity as
measured by FACE. Statistical comparisons among water
concentration, DNA, cells, GAG class concentrations, pro-
portions, or chain lengths in the two myxomatous groups
and the normal group were obtained using an analysis of
variance, followed by Tukey tests as needed. Because of the
large number of statistical tests performed, two-tailed sig-
nificance was accepted at p  0.01.
RESULTS
Water, DNA, collagen, and total GAG concentrations.
The water content in all leaflets was greater than that in the
chordae (p  0.001) (Table 2). Water content was higher
than normal in chordae from ULP and highest in the
leaflets and chordae from BLP (all p  0.001). Deoxyribo-
nucleic acid concentration relative to dry weight was equiv-
alent between leaflets and chordae in all groups, significantly
higher than normal in myxomatous tissues (p  0.001), and
slightly higher for BLP than for ULP (p  0.05). Normal-
izing DNA to wet weight, however, eliminated the signif-
icant differences in DNA concentration between groups
(data not shown), indicating that the volumetric cell density
of the more hydrated myxoid tissues was equivalent to that
of the less hydrated normals.
In general, the collagen concentration in chordae was
greater than in the leaflets in both normal and myxomatous
valves (Table 2). Collagen concentration in myxomatous
leaflets was slightly elevated when normalized to tissue dry
weight (p  0.077). Because of high water contents,
normalizing collagen to wet weight resulted in lower colla-
gen concentrations in the myxomatous leaflets as compared
with normal (p  0.002), suggesting that the mechanical
load-bearing capabilities of collagen are distributed across a
larger loading region.
Leaflets had a greater GAG concentration than chordae
when expressed in terms of dry weight (p  0.001).
Myxomatous valve chordae had significantly higher GAG
concentrations than normals (p  0.005), whereas the
GAG concentrations in leaflets from ULP were slightly
elevated (p  0.05). Chordae from ULP valves had greater
GAG concentrations than chordae from BLP valves (p 
0.001), although the leaflet differences were not significant.
The differences among the ULP and normal leaflets and
chordae retained approximately the same levels of signifi-
cance even after normalizing data to wet weights.
Individual GAG class concentrations. In normal leaflets,
the most common GAGs were HA, dermatan-4-sulfate
Figure 1. Hyaluronidase SD and chondroitinase ABC (HABC) and
chondroitinase ACII (AC2) digests of leaflet and chordae, with the first
lane showing monosaccharide/disaccharide standard (STD) bands. The
4S- and 6S-galNAc (N-acetylgalactosamine-4- and 6-sulfate) are the
non-reducing terminal ends of the GAG chains. Di0S  unsulfated
chondroitin; Di2S  chondroitin/dermatan 2-sulfate; Di4S  chon-
droitin/dermatan-4-sulfate; Di6S  chondroitin/dermatan-6-sulfate;
Di4,6S  chondroitin/dermatan-4,6-sulfate; DiHA  hyaluronan.
Table 2. Concentrations of Water, DNA, Collagen, and Total GAGs
Normal
Leaflets
ULP
Leaflets
BLP
Leaflets
Normal
Chordae
ULP
Chordae
BLP
Chordae
Water (% of wet weight) 87.0  3.5 88.3  1.9 89.4  1.6†‡ 75.7  6.5* 79.0  7.3*† 82.6  5.7*†‡
Collagen (% of dry weight) 50.8  13.5 57.8  14.2 54.5  13.7 63.2  11.6* 65.6  13.8* 61.3  15.1
DNA (mg/g dry weight) 3.1  1.7 4.3  2.2† 5.1  2.0† 2.9  1.5 4.2  2.1† 4.6  1.7†
Hexuronic acid (mg/g dry weight) 4.5  2.1 6.5  3.1 5.9  3.4 2.4  1.2* 6.0  2.7† 3.7  2.1*†‡
Data are given as mean  standard deviation. *p  0.05 chordae vs. leaflets; †p  0.05 ULP or BLP vs. normal; ‡p  0.05, ULP vs. BLP.
BLP  bileaflet; DNA  deoxyribonucleic acid; GAGs  glycosaminoglycans; ULP  unileaflet prolapse.
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(D-4-S), and chondroitin-6-sulfate (C-6-S) (Fig. 2). Myx-
omatous leaflets, however, had more C-6-S (BLP, p 
0.033; ULP, p  0.009) and slight elevations in almost
every other GAG class (with respect to dry weight). Normal
chordae contained predominantly D-4-S, with less HA and
C-6-S. The myxomatous chordae had elevated concentra-
tions of HA, unsulfated chondroitin, chondroitin-4-sulfate,
and C-6-S (p  0.003). The relative changes in GAG
concentrations were far greater in myxomatous chordae than
that in the leaflets. Although there were no differences
between the two myxomatous leaflet groups, ULP chordae
contained slightly more HA and C-6-S than did the BLP
chordae (p  0.05).
Myxoid valves also contained altered proportions of the
various GAG classes (Fig. 3). Myxomatous leaflets from
ULP had slightly greater proportions of C-6-S than normal
leaflets (p  0.013), whereas leaflets from BLP had signif-
icantly greater proportions of C-6-S (p  0.002) and
slightly lower proportions of D-4-S (p 0.035), but overall
there were few differences between groups. The myxoma-
tous chordae, however, had slightly greater proportions of
HA (p  0.05), significantly greater proportions of C-6-S
(p  0.001), and lower proportions of D-4-S (p  0.001)
and oversulfated CS/DS (p  0.004) than did normal
chordae. The changes in the GAG class proportions were
therefore greater in the myxoid chordae than they were in
the myxoid leaflets, although they showed the same general
trends.
GAG chain length. In normal mitral valves, the CS/DS
chains were longer in leaflets than in chordae (p  0.001)
(Fig. 4). In myxomatous valves, no such difference was
found. There was also no difference in chain lengths
between leaflets from ULP and normal valves, but leaflets
from valves with BLP contained longer GAG chains (p 
0.004). Chordae from myxomatous valves contained longer
GAG chains than did normal chordae (p  0.001).
DISCUSSION
The first major finding of this study was that the biochem-
ically measurable effects of myxomatous mitral valve disease
and the differences between ULP and BLP valves appear to
be more pronounced in chordae than in leaflets. These
greater magnitude changes in the chordae support our
previous mechanical findings (15–17), in which both myx-
omatous leaflets and chordae were more extensible and less
stiff than normal tissues, but changes in stiffness and failure
strength were more severe in the chordae. Our mechanical
Figure 2. Concentrations of individual glycosaminoglycan (GAG) classes. C-0-S  unsulfated chondroitin; C-4-S  chondroitin-4-sulfate; C-6-S 
chondroitin-6-sulfate; D-4-S  dermatan-4-sulfate; D-6-S  dermatan-6-sulfate; HA  hyaluronan; XS  oversulfated chondroitin/dermatan sulfate.
*p  0.05, chordae versus leaflets; †p  0.05, unileaflet prolapse (ULP) or bileaflet prolapse (BLP) versus normal.
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and biochemical findings are therefore consistent with the
clinical observations that chordal rupture and elongation are
the most frequent mechanisms responsible for myxomatous
mitral regurgitation (3).
The second finding was that myxomatous and normal
chordae contain distinctly different “profiles” of individual
GAG classes. Normal chordae contained primarily D-4-S
in chains approximately 50 to 60 disaccharides long,
whereas the myxomatous chordae had greater proportions
of C-6-S and HA, a reduced proportion of D-4-S, and
significantly longer CS/DS chains. The GAG profile of
myxomatous chordae was therefore less like normal chordae
and more like normal and myxomatous leaflets. The GAG
profile of myxomatous leaflets was almost uniformly ele-
vated across all the GAG classes but was otherwise essen-
tially unchanged from that of normal leaflets. Interestingly,
although HA had previously been suggested as the GAG
mainly responsible for the myxomatous change (10,13,14),
we found that the GAG most elevated was C-6-S. We
attribute this new finding to the sensitivity and repeatability
of the FACE methodology in resolving the different GAG
classes. Otherwise, the changes in the collagen, DNA, and
hexuronic acid concentrations described here are in almost
complete agreement with findings from previously pub-
lished studies (8–10).
We interpret the elevation of HA and C-6-S in myxo-
matous chordae as indicating a likely overabundance of the
proteoglycan versican (23,24). Versican is one of the largest
proteoglycans, containing a 450-kD core protein sur-
Figure 3. Proportions of different glycosaminoglycan classes. C-0-S  unsulfated chondroitin; C-4-S  chondroitin-4-sulfate; C-6-S  chondroitin-6-
sulfate; D-4-S  dermatan-4-sulfate; D-6-S  dermatan-6-sulfate; HA  hyaluronan; XS  oversulfated chondroitin/dermatan sulfate.*p  0.05,
unileaflet prolapse (ULP) or bileaflet prolapse (BLP) versus normal.
Figure 4. Lengths of chondroitin/dermatan sulfate chains. *p  0.05,
chordae versus leaflets; †p  0.05, unileaflet prolapse (ULP) or bileaflet
prolapse (BLP) versus normal; ‡p  0.05, ULP versus BLP. GAG 
glycosaminoglycan.
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rounded by 15 to 20 long GAG chains (23), which extend
outward from the core protein to create a highly structured,
negatively charged macromolecule that frequently binds
with HA (24). Thus, it is thought that the versican-HA
aggregate provides soft tissues with hydration and compres-
sive resistance (11). An abundance of this proteoglycan
aggregate would explain the thickened, spongy appearance
of myxomatous valves, particularly in the enlarged, hy-
drated, translucent spongiosa. Versican also reportedly has
an inverse relationship with elastin: CS chains, such as those
found in versican, inhibited the in vitro assembly of tro-
poelastin into mature insoluble elastic fibers (25), whereas
overexpression of a versican variant without any GAG
chains produced the opposite effect (26). The overabun-
dance of versican-associated GAGs may lead to the defi-
cient elastic fibers found in myxomatous valves (6).
In myxomatous valves—and chordae in particular—the
relative increase in the proportion of HA and long-chain
C-6-S was accompanied by a relative decrease in the
proportion of 4-sulfated GAGs with shorter chain lengths.
These 4-sulfated GAGs are commonly found in the small
proteoglycans decorin and biglycan (27). Decorin binds to
type I collagen and has been shown to control collagen
fibrillogenesis (11). Although the elevated collagen concen-
tration measured in this study did not reach statistical
significance, an increase in the ratio of collagen to decorin-
associated GAGs suggests an impairment in type I collagen
fibrillogenesis and/or the synthesis of alternative types of
collagen, such as type III (10), which may not provide the
same mechanical strength as type I collagen.
Finally, we provide the first findings that ULP and BLP
are two biochemically distinct variants of myxomatous
mitral valve disease. The chordae from valves with ULP
contained more GAGs, whereas leaflets and chordae from
valves with BLP contained more water. Compared with
valves from ULP, the leaflets and chordae from valves with
BLP had more cells but slightly less collagen. Because
differences in biochemical makeup can influence material
properties, our finding of biochemical differences among
subgroups of myxoid valves supports our previous report of
mechanical and echocardiographic diversity between ULP
and BLP (17).
Study limitations. One possible limitation of this study is
the slightly lower mean age of the control group. Several
previous studies, however, have shown that the concentra-
tions of total GAGs, CS (12), and cells (28) in human heart
valves decrease with age. Therefore, our younger normal
control group underestimates, rather than exaggerates, the
findings of our study.
Our proposed explanation for these findings is that the
matrix and mechanics of myxomatous chordae are shifting
from a normal “chordal phenotype” involving high-tensile
loads toward a “leaflet phenotype” involving a combination
of compressive and low-tensile loads. It will be important to
determine whether the stimulus for this phenotypic shift is
genetically based (perhaps related to a heritable connective
tissue disorder or a unique aspect of valvular interstitial cells)
or is a secondary response to the altered mechanical forces in
the regurgitant valve. Although we cannot conclusively
establish whether these biochemical changes precipitate the
original myxomatous valve dysfunction, these findings
nonetheless illuminate the relationships among the altered
extracellular matrix, tissue mechanics, and function of myx-
omatous valves. Our interpretation that these biochemical
changes may be responsible for, or perpetuated by, the
altered mechanical loads in a vicious cycle of myxomatous
degeneration provides additional support for the mechanism
of myxomatous pathogenesis recently proposed by Rabkin et
al. (5).
Conclusions. These findings show that the mitral valve
chordae are more severely affected by myxomatous changes
than leaflets and substantiate our hypothesis that there is a
biochemical basis for the varying functional severity of the
myxomatous mitral valve disease.
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